Identification

Generic Name
Nicotinamide Mononucleotide
DrugBank Accession Number
DB03227
Background

3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 335.2271
Monoisotopic: 335.06442701
Chemical Formula
C11H16N2O8P
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UADP-ribosyl cyclase 2Not AvailableHumans
UNicotinamide mononucleotide adenylyltransferase 1Not AvailableHumans
UNicotinamide mononucleotide adenylyltransferase 3Not AvailableHumans
UDNA ligaseNot AvailableEnterococcus faecalis (strain ATCC 700802 / V583)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Alpha9Powder45 mg/100mgTopicalGolden Life Health Products Limited2020-12-23Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
NmnNicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)TabletOralIDun Bio-Technology Limited2021-06-222021-06-28US flag
NmnNicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)CapsuleOralIDun Bio-Technology Limited2021-09-09Not applicableUS flag
NmnNicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)CapsuleOralIDun Bio-Technology Limited2021-06-22Not applicableUS flag
Nmn.5sNicotinamide Mononucleotide (354 mg/1) + Resveratrol (60 mg/1)TabletOralChengdu Heqi Cosmetics Co., Ltd2021-03-05Not applicableUS flag
NmnpqqNicotinamide Mononucleotide (45 mg/100mg) + Pyrroloquinoline Quinone (10 mg/100mg)PowderTopicalGolden Life Health Products Limited2020-12-23Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Alpha9Nicotinamide Mononucleotide (45 mg/100mg)PowderTopicalGolden Life Health Products Limited2020-12-23Not applicableUS flag
NmnNicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)CapsuleOralIDun Bio-Technology Limited2021-09-09Not applicableUS flag
NmnNicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)CapsuleOralIDun Bio-Technology Limited2021-06-22Not applicableUS flag
NmnNicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)TabletOralIDun Bio-Technology Limited2021-06-222021-06-28US flag
Nmn.5sNicotinamide Mononucleotide (354 mg/1) + Resveratrol (60 mg/1)TabletOralChengdu Heqi Cosmetics Co., Ltd2021-03-05Not applicableUS flag
NmnpqqNicotinamide Mononucleotide (45 mg/100mg) + Pyrroloquinoline Quinone (10 mg/100mg)PowderTopicalGolden Life Health Products Limited2020-12-23Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as nicotinamide nucleotides. These are pyridine nucleotides, in which the pyridine base is nicotinamide or a derivative thereof.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Pyridine nucleotides
Sub Class
Nicotinamide nucleotides
Direct Parent
Nicotinamide nucleotides
Alternative Parents
Pentose phosphates / Glycosylamines / Monosaccharide phosphates / Nicotinamides / Monoalkyl phosphates / Pyridinium derivatives / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols
show 9 more
Substituents
1,2-diol / Alcohol / Alkyl phosphate / Aromatic heteromonocyclic compound / Azacycle / Carboxamide group / Carboxylic acid derivative / Glycosyl compound / Heteroaromatic compound / Hydrocarbon derivative
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
2KG6QX4W0V
CAS number
Not Available
InChI Key
DAYLJWODMCOQEW-WYOJIJJFSA-O
InChI
InChI=1S/C11H15N2O8P/c12-10(16)6-2-1-3-13(4-6)11-9(15)8(14)7(21-11)5-20-22(17,18)19/h1-4,7-9,11,14-15H,5H2,(H3-,12,16,17,18,19)/p+1/t7-,8-,9+,11+/m0/s1
IUPAC Name
3-carbamoyl-1-[(2R,3R,4R,5S)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-1lambda5-pyridin-1-ylium
SMILES
NC(=O)C1=CC=C[N+](=C1)[C@@H]1O[C@@H](COP(O)(O)=O)[C@H](O)[C@H]1O

References

General References
Not Available
PubChem Compound
6093202
PubChem Substance
46506664
ChemSpider
26329944
RxNav
2262276
ChEBI
50383
ZINC
ZINC000053684234
PDBe Ligand
NMN

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedOtherAging / Coronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
PowderTopical45 mg/100mg
CapsuleOral
TabletOral
PowderTopical
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.8 mg/mLALOGPS
logP-1.5ALOGPS
logP-6.2Chemaxon
logS-2.3ALOGPS
pKa (Strongest Acidic)1.21Chemaxon
pKa (Strongest Basic)-1.6Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area163.42 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity71.71 m3·mol-1Chemaxon
Polarizability29.2 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9823
Blood Brain Barrier+0.8201
Caco-2 permeable-0.7581
P-glycoprotein substrateNon-substrate0.8055
P-glycoprotein inhibitor INon-inhibitor0.9235
P-glycoprotein inhibitor IINon-inhibitor0.9557
Renal organic cation transporterNon-inhibitor0.9492
CYP450 2C9 substrateNon-substrate0.8213
CYP450 2D6 substrateNon-substrate0.8413
CYP450 3A4 substrateNon-substrate0.5593
CYP450 1A2 substrateNon-inhibitor0.9013
CYP450 2C9 inhibitorNon-inhibitor0.9087
CYP450 2D6 inhibitorNon-inhibitor0.912
CYP450 2C19 inhibitorNon-inhibitor0.8846
CYP450 3A4 inhibitorNon-inhibitor0.9644
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9795
Ames testNon AMES toxic0.8159
CarcinogenicityNon-carcinogens0.9131
BiodegradationNot ready biodegradable0.6569
Rat acute toxicity2.3780 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9903
hERG inhibition (predictor II)Non-inhibitor0.8268
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transferase activity
Specific Function
Synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger that elicits calcium release from intracellular stores. May be involv...
Gene Name
BST1
Uniprot ID
Q10588
Uniprot Name
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2
Molecular Weight
35723.545 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Nicotinate-nucleotide adenylyltransferase activity
Specific Function
Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can u...
Gene Name
NMNAT1
Uniprot ID
Q9HAN9
Uniprot Name
Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1
Molecular Weight
31932.22 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Nicotinate-nucleotide adenylyltransferase activity
Specific Function
Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can u...
Gene Name
NMNAT3
Uniprot ID
Q96T66
Uniprot Name
Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 3
Molecular Weight
28321.525 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Kind
Protein
Organism
Enterococcus faecalis (strain ATCC 700802 / V583)
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
DNA ligase that catalyzes the formation of phosphodiester linkages between 5'-phosphoryl and 3'-hydroxyl groups in double-stranded DNA using NAD as a coenzyme and as the energy source for the react...
Gene Name
ligA
Uniprot ID
Q837V6
Uniprot Name
DNA ligase
Molecular Weight
75583.155 Da

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52